Amgen Buys Horizon, Mirati’s KRAS Drug OK, & Nimbus’s Tyk2 Windfall

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

UK Clears 1st CRISPR Drug, Lilly’s siRNA for CV Disease & Blackstone’s Anti-Clotting Win
Obesity Drug Rivalry Intensifies, Takeda’s Big FDA Week, & Vor Takes on AML
Lilly Doubles Down on Base Editing, BioMarin CEO Exits, and Layoffs Mount
Merck’s ADC Wager, Roche Enters TL1A Rivalry, & OrbiMed Signals Time to Buy